NLRP3 and diabetic cardiomyopathy: Protocatechualdehyde (compound 4) was identified as a potential component that ameliorated streptozotocin-induced diabetic cardiomyopathy in mice through inhibiting the activation of the NLRP3 inflammasome [81]; this may also contribute to PD treatment through its anti-inflammatory activity.